Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 199

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 199
---
 exclusive, or non-exclusive
licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the
invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements
for public use under federal regulations (also referred to as march-in rights). If the U.S. government exercised its march-in rights in
our current or future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be
forced to license or sublicense intellectual property developed by us or that we license on terms unfavorable to us, and there can be
no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also has
the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file
an application to register the intellectual property within specified time limits. Intellectual property generated under a government
funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources.
In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these
inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that
provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been
made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States
or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability
to contract with non-U.S. product manufacturers for products covered by such intellectual property.

50

We license our patents from others. If such
owners do not properly maintain or enforce the intellectual property underlying such licenses, our competitive position and business prospects
could be harmed. Our licensors may also seek to terminate our license.

We are a party to a number of licenses that give us rights to third-party
intellectual property that is necessary or useful to our business. To this end, we are dependent on our licenses with Xencor, Inc., Immune
Ventures, LLC, the University of Pittsburgh and GOSH. Our success will depend in part on the ability of our licensors to obtain, maintain
and enforce our licensed intellectual property.